Literature DB >> 3277988

Comparison of Western blot (immunoblot) based on recombinant-derived p41 with conventional tests for serodiagnosis of human immunodeficiency virus infections.

J M Hofbauer1, T F Schulz, P Hengster, C Larcher, R Zangerle, H Kofler, P Fritsch, H Wachter, M P Dierich.   

Abstract

To evaluate the performance of a serological test for human immunodeficiency virus type 1 (HIV-1) infections based on the use of a recombinant envelope gene-derived protein as the antigen, we caused expression of a 1.4-kilobase fragment of HIV.DNA that codes for the complete gp41 transmembrane protein in an Escherichia coli expression vector and used Western blots (WB; immunoblots) prepared with recombinant material (pEX-41) to detect antibodies to HIV-1. This test detected all 339 sera which were positive by a combination of conventional serodiagnostic assays and produced no false-positive results with 311 negative samples. Also no false-positive results were obtained with 20 sera from systemic lupus erythematosus patients which had high titers of cross-reactive autoantibodies. In six cases, the pEX-41 WB proved to be more sensitive than individual assays applied on their own, and in five cases it was even more sensitive than a combination of conventional assays. We tested 221 sera in both our pEX-41 WB and a commercially available recombinant enzyme immunoassay (EIA [Abbott]). The results were identical in 188 cases. A total of 27 sera containing antibodies to gp41 as demonstrated in the pEX-41 WB, as well as the Abbott recombinant EIA, had no antibodies to the recombinant core antigen as measured in the Abbott EIA. However, 25 of these sera did stain the 24-kilodalton band on a WB with purified virus. Six sera that were positive in all of the conventional confirmatory assays and reacted strongly with the pEX-41 WB did not recognize the surface antigen used in the Abbott recombinant EIA. We conclude that the use of WB prepared with recombinant-derived p41 offers a very sensitive and specific method to detect antibodies to HIV.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3277988      PMCID: PMC266210          DOI: 10.1128/jcm.26.1.116-120.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Expression in Escherichia coli of open reading frame gene segments of HTLV-III.

Authors:  N T Chang; P K Chanda; A D Barone; S McKinney; D P Rhodes; S H Tam; C W Shearman; J Huang; T W Chang; R C Gallo
Journal:  Science       Date:  1985-04-05       Impact factor: 47.728

3.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.

Authors:  H Towbin; T Staehelin; J Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1979-09       Impact factor: 11.205

4.  [Detection of antibodies to HTLV-III: a comparison of various ELISA methods as screening tests and the Western Blot with immunofluorescence as confirmatory procedures].

Authors:  P Hengster; C Larcher; E Pöckl; T Schulz; H Wachter; M P Dierich
Journal:  Wien Klin Wochenschr       Date:  1987-02-20       Impact factor: 1.704

5.  A glycopolypeptide (gp 100) is the main antigen detected by HTLV-III antisera.

Authors:  J Schneider; H Bayer; U Bienzle; G Hunsmann
Journal:  Med Microbiol Immunol       Date:  1985       Impact factor: 3.402

6.  HTLV-III env gene products synthesized in E. coli are recognized by antibodies present in the sera of AIDS patients.

Authors:  R Crowl; K Ganguly; M Gordon; R Conroy; M Schaber; R Kramer; G Shaw; F Wong-Staal; E P Reddy
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

7.  An HTLV-III peptide produced by recombinant DNA is immunoreactive with sera from patients with AIDS.

Authors:  N T Chang; J Huang; J Ghrayeb; S McKinney; P K Chanda; T W Chang; S Putney; M G Sarngadharan; F Wong-Staal; R C Gallo
Journal:  Nature       Date:  1985 May 9-15       Impact factor: 49.962

8.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

9.  HTLV-III in symptom-free seronegative persons.

Authors:  S Z Salahuddin; J E Groopman; P D Markham; M G Sarngadharan; R R Redfield; M F McLane; M Essex; A Sliski; R C Gallo
Journal:  Lancet       Date:  1984-12-22       Impact factor: 79.321

10.  Construction of a new family of high efficiency bacterial expression vectors: identification of cDNA clones coding for human liver proteins.

Authors:  K K Stanley; J P Luzio
Journal:  EMBO J       Date:  1984-06       Impact factor: 11.598

View more
  9 in total

1.  Evaluation of a line immunoassay for the differential detection of antibodies to human immunodeficiency virus.

Authors:  R Vranckx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

2.  Passive hemagglutination test for detection of antibodies to human immunodeficiency virus type 1 and comparison of the test with enzyme-linked immunosorbent assay and Western blot (immunoblot) analysis.

Authors:  M B Vasudevachari; K W Uffelman; T C Mast; R L Dewar; V Natarajan; H C Lane; N P Salzman
Journal:  J Clin Microbiol       Date:  1989-01       Impact factor: 5.948

3.  Reliable confirmation of antibodies to human immunodeficiency virus type 1 (HIV-1) with an enzyme-linked immunoassay using recombinant antigens derived from the HIV-1 gag, pol, and env genes.

Authors:  V L Ng; C S Chiang; C Debouck; M S McGrath; T H Grove; J Mills
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

4.  Molecular cloning of two west African human immunodeficiency virus type 2 isolates that replicate well in macrophages: a Gambian isolate, from a patient with neurologic acquired immunodeficiency syndrome, and a highly divergent Ghanian isolate.

Authors:  H Kühnel; H von Briesen; U Dietrich; M Adamski; D Mix; L Biesert; R Kreutz; A Immelmann; K Henco; C Meichsner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

5.  Cleavage of procaryotically expressed human immunodeficiency virus fusion proteins by factor Xa and application in western blot (immunoblot) assays.

Authors:  S Ellinger; R Glockshuber; G Jahn; A Plückthun
Journal:  J Clin Microbiol       Date:  1989-05       Impact factor: 5.948

6.  Quantitative western immunoblotting analysis in survey of human immunodeficiency virus-seropositive patients.

Authors:  D G Schiavini; J M Puel; S A Averous; J A Bazex
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

Review 7.  Differential diagnosis of human retrovirus infections in the laboratory.

Authors:  B P Griffith
Journal:  Yale J Biol Med       Date:  1989 Mar-Apr

8.  An Accurate Confirmation of Human Immunodeficiency Virus Type 1 (HIV-1) and 2 (HIV-2) Infections with a Dot blot assay Using Recombinant p24, gp41, gp120 and gp36 Antigens.

Authors:  Mehrdad Ravanshad; Farzaneh Sabahi; Fereidoun Mahboudi; Mohammad Hassan Roostaee; Ramin Sarami Forooshani; Anoshiravan Kazemnejad
Journal:  Int J Med Sci       Date:  2004-10-15       Impact factor: 3.738

Review 9.  Mapping of viral epitopes with prokaryotic expression products.

Authors:  J A Lenstra; J G Kusters; B A van der Zeijst
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.